Q-omics provides the consensus-scored EDNRB profile across patient tissues and cancer cell-line models. EDNRB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, EDNRB is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, EDNRB RNA expression shows 23,350 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where EDNRB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EDNRB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EDNRB survival associations across molecular data types. EDNRB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EDNRB RNA expression–survival associations across cancer types. High EDNRB expression shows unfavorable associations in MESO and ACC, but favorable associations in KIRC, HNSC, UVM and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for EDNRB RNA expression.
This table summarizes EDNRB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for EDNRB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EDNRB shows lower tumor expression in BLCA, COAD, KICH, LUAD and LUSC and higher tumor expression in KIRC. The BLCA box plot shows higher EDNRB RNA expression in normal versus tumor tissue (log2 FC = −2.313, t-test p < 0.001).
This table shows molecular features associated with EDNRB in patient tissues and cancer cell lines. In patient samples, EDNRB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, EDNRB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
